Search
Tosatoxumab
go.drugbank.com/drugs/DB16557InvestigationalTosatoxumab is a fully-human monoclonal antibody (IgG1λ) targeting the Staphylococcus aureus alpha-toxin or the S. aureus alpha-hemolysin[A191829, L31568, L31573] and thereby preserving human immune cells
Lumicitabine
go.drugbank.com/drugs/DB14808InvestigationalLumicitabine is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and
PGX-100
go.drugbank.com/drugs/DB06114InvestigationalPGX-100 is an intravenous dosage form of modified heparin. … It is a nearly nonanticoagulant heparin derivative that retains its anti-inflammatory activity.
PRO-542
go.drugbank.com/drugs/DB05793InvestigationalPRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from entering and infecting cells. … PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutralizes primary HIV-1 isolates.
Gallium maltolate
go.drugbank.com/drugs/DB05420InvestigationalGallium maltolate is Titan’s novel oral agent in development for the potential treatment of chronic bacterial infections, bone disease and cancer.
INCB7839
go.drugbank.com/drugs/DB05033InvestigationalINCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways. … It represents a potentially important new class of targeted breast cancer therapy. It has shown promising clinical activity in heavily pretreated, refractory breast cancer patients.
Aranidipine
go.drugbank.com/drugs/DB09229ExperimentalIt is a calcium antagonist with the formula methyl 2-oxopropyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate. … Aranidipine is a novel dihydropyridine derivative that gives rise to two active metabolites (M-1α and M-1β) that exhibit hypotensive activity.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTezacitabine
go.drugbank.com/drugs/DB06433InvestigationalA synthetic purine nucleoside analogue with potential antineoplastic activity.
CR002
go.drugbank.com/drugs/DB05139InvestigationalCR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived growth factor-D (PDGF-D), a target shown to play a role in kidney inflammation. … This is a novel therapeutic approach to treat kidney inflammation.